Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 920,774 | 2,089,719 | 4,401,024 | 3,151,961 | 2,152,278 |
| Marketable Securities | 691,163 | 2,640,026 | 3,001,322 | 2,547,399 | 2,229,371 |
| Receivables | 10,446,800 | 10,927,900 | 9,046,744 | 10,303,120 | 8,346,416 |
| Inventories | 4,892,160 | 4,618,957 | 4,311,964 | 4,093,722 | 3,691,122 |
| Other current assets | 2 | -2 | -4 | -2 | 3 |
| TOTAL | $16,950,900 | $20,276,600 | $20,761,050 | $20,096,200 | $16,419,190 |
| Non-Current Assets | |||||
| PPE Net | 14,302,290 | 13,207,540 | 11,893,310 | 10,961,010 | 10,089,020 |
| Investments And Advances | 240,386 | 241,468 | 214,766 | 216,082 | 174,505 |
| Intangibles | 8,683,584 | 8,770,951 | 8,135,996 | 7,414,429 | 7,275,465 |
| Other Non-Current Assets | 3,345,740 | 3,166,811 | 2,809,618 | 2,330,289 | 2,070,430 |
| TOTAL | $26,572,000 | $25,386,770 | $23,053,690 | $20,921,810 | $19,609,420 |
| Total Assets | $43,522,900 | $45,663,370 | $43,814,750 | $41,018,010 | $36,028,600 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,479,878 | 940,606 | 965,498 | 918,823 | 180,269 |
| Accounts payable and accrued liabilities | 1,893,674 | 3,717,991 | 2,935,476 | 2,598,827 | 1,448,205 |
| Other current liabilities | 19,870,320 | 18,942,070 | 19,496,260 | 17,959,200 | 16,513,570 |
| TOTAL | $24,112,230 | $24,633,910 | $25,192,590 | $22,881,890 | $19,015,580 |
| Non-Current Liabilities | |||||
| Long Term Debt | 2,440,838 | 2,980,666 | 2,908,904 | 2,836,531 | 3,496,875 |
| Other Non-Current Liabilities | 1,161,306 | 1,100,616 | 985,354 | 967,182 | 871,517 |
| TOTAL | $5,009,222 | $5,556,804 | $5,045,468 | $4,918,018 | $5,503,179 |
| Total Liabilities | $29,121,460 | $30,190,710 | $30,238,060 | $27,799,910 | $24,518,760 |
| Shareholders' Equity | |||||
| Common Shares | 65,666 | 65,485 | 65,846 | 65,891 | 65,710 |
| Retained earnings | 14,421,680 | 15,222,620 | 13,393,310 | 12,874,040 | 11,105,790 |
| Other shareholders' equity | -84,906 | 185,555 | 118,534 | 278,179 | 339,340 |
| TOTAL | $14,401,440 | $15,472,660 | $13,576,690 | $13,218,110 | $11,509,840 |
| Total Liabilities And Equity | $43,522,900 | $45,663,370 | $43,814,750 | $41,018,020 | $36,028,600 |